Healthcare
Live Price
Offline$2.57
+3.63% today
1Y Change
-4.78%
Window
Jun 25, 2025 โ Jun 23, 2026
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Codexis Inc. (CDXS) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $2.57 and down 4.8% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +18.6%, EPS growth of +43.8%, a dividend yield of 0.0%. What stands out right now is revenue +18.6%, EPS +43.8%, free cash flow +55.6% with operating margin -54.5% and ROIC -30.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CDXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.6% vs +7.6% peer median
Operating Margin
Below sector median
-54.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +18.6% and EPS at +43.8%, with operating margin around -54.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +2.8% | +3.2% | -3.6% |
2026 Mar 11, 2026 | +1000.0% | +34.6% | +15.7% | +89.0% |
2025 Nov 6, 2025 | -46.7% | -17.2% | -20.1% | -10.3% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CDXS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CDXS Max Drawdown
-70.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CDXS and SPY.
Company Overview
Codexis Inc.
NASDAQ
Codexis Inc. is a leading enzyme engineering company that develops scalable, sustainable enzymatic solutions for therapeutic manufacturing and development. It leverages the proprietary CodeEvolver protein engineering technology platform to design and optimize novel enzymes that outperform traditional methods, enabling efficient production with fewer impurities, reduced waste, and lower energy use. The company operates through two main segments: Performance Enzymes, which commercializes enzyme products and technologies primarily for the pharmaceuticals market, including applications in RNAi therapeutics manufacturing via the ECO Synthesis platform; and Novel Biotherapeutics, which focuses on discovering and improving biotherapeutic drug candidates. Codexis Inc. also provides enzymes for precision diagnostics, such as Codex HiFi Hot Start DNA Polymerase and screening kits, along with services supporting small molecule manufacturing. These offerings serve partners in therapeutics development across regions including the United States, Europe, Asia, and beyond. Founded in 2002 and headquartered in Redwood City, California, Codexis Inc. plays a key role in advancing enzymatic manufacturing innovations for the biotechnology and pharmaceutical industries.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.